About: Bone marrow transplantation for thalassemia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Bone marrow transplantation for thalassemia Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Bone marrow transplantation for thalassemia
Creator	Angelucci, E Baronciani, D Erer, B Galimberti, M Giardini, C Polchi, P Lucareili, G
Source	PMC
abstract	Early trials of allogeneic bone marrow transplantation (BMT) for homozygous beta-thalassemia and the analyses of results of transplantation in patients less then 16 years old have allowed us to identify three classes of risk using the criteria of degree of hepatomegaly, the degree of portal fibrosis and the quality of the chelation treatment given before the transplant. Patients for whom all three criteria were adverse constituted class 3, patients with none of the adverse criteria constituted class one and patients with one or various association of the adverse criteria formed Class 2. Most patients older than 16 years have disease characteristics that place them in class 3 with very few in class 2. For all the patients with an HLA identical donor we are actually using two Protocols for BMT to whom the patients are assigned on the base of the class they belong to at the time of BMT and independently on the age of the patient. For class 1, class 2 and for class 3 the probabilities of survival and of event-free-survival are respectively of 98% and 94%, 87% and 84%, 100% and 67%. For those patients that were older than 16 years at the time of the transplant, the probabilities of survival are 82% and the probabilities of event-free survival are 79%. Bone marrow transplantation is a new form of radical treatment of thalassemia in those patients with an HLA identical donor.
has issue date	1993-01-01(xsd:dateTime)
bibo:doi	10.1007/bf02751428
bibo:pmid	8262588
has license	no-cc
sha1sum (hex)	1607578ee7aac5699e3d22661ecffac0c51083ef
schema:url	https://doi.org/10.1007/bf02751428
resource representing a document's title	Bone marrow transplantation for thalassemia
has PubMed Central identifier	PMC7102227
has PubMed identifier	8262588
schema:publication	Indian J Pediatr
resource representing a document's body	covid:1607578ee7aac5699e3d22661ecffac0c51083ef#body_text
is schema:about of	named entity 'ALLOGENEIC BONE MARROW TRANSPLANTATION' named entity '100%' named entity 'AGE' named entity 'CLASS 1' named entity 'FORMED' named entity 'ALLOWED' named entity 'OLD' named entity 'DEGREE' named entity 'TRANSPLANTATION' named entity 'CLASSES' named entity 'fibrosis' named entity 'HLA' named entity 'Class 2' named entity 'beta-thalassemia' named entity 'Karnofsky' named entity 'aplasia' named entity 'infectious diseases' named entity 'T-cell' named entity 'GvHD' named entity 'septicemia' named entity 'Bone marrow transplantation' named entity 'red blood cell' named entity 'Epstein-Barr virus' named entity 'visceral leishmaniasis' named entity 'ineffective erythropoiesis' named entity 'prophylaxis' named entity 'thalassemia' named entity 'GvHD' named entity 'liver' named entity 'bone marrow transplant' named entity 'chelated' named entity 'red blood cells' named entity 'prophylaxis' named entity 'T-cell' named entity 'pubertal maturation' named entity 'splenomegaly' named entity 'HLA' named entity 'genetic defect' named entity 'vitamin' named entity 'onchocerciasis' named entity 'infectious diseases' named entity 'risk factors' named entity 'cytogenetic studies' named entity 'pulmonary insufficiency' named entity 'thalassemia' named entity 'risk factors' named entity 'thalassemia' named entity 'Bone marrow transplantation' named entity 'cyclophosphamide' named entity 'GvHD' named entity 'hepatomegaly' named entity 'malignancies' named entity 'homozygous' named entity 'hepatitis' named entity 'blood transfusions' named entity 'risk factors' named entity 'aplasia' named entity 'CD4' named entity 'histopathological' named entity 'desferrioxamine' named entity 'vitamin' named entity 'blood products' named entity 'vitamin A deficiency' named entity 'risk factors' named entity 'infection' named entity 'splenectomy' named entity 'genetic defect' named entity 'vitamin supplementation' named entity 'fibrosis' named entity 'lymphoma' named entity 'tuberculosis' named entity 'prophylaxis' named entity 'liver' named entity 'vitamin A deficiency' named entity 'immunosuppressive'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software